GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Five Prime Therapeutics Inc (NAS:FPRX) » Definitions » Interest Coverage

Five Prime Therapeutics (Five Prime Therapeutics) Interest Coverage : N/A (As of Dec. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Five Prime Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Five Prime Therapeutics's Operating Income for the three months ended in Dec. 2020 was $-21.98 Mil. Five Prime Therapeutics's Interest Expense for the three months ended in Dec. 2020 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies interest coverage is at least 5. Five Prime Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Five Prime Therapeutics's Interest Coverage or its related term are showing as below:


FPRX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Five Prime Therapeutics Interest Coverage Historical Data

The historical data trend for Five Prime Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Five Prime Therapeutics Interest Coverage Chart

Five Prime Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt N/A N/A

Five Prime Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Five Prime Therapeutics's Interest Coverage

For the Biotechnology subindustry, Five Prime Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Five Prime Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Five Prime Therapeutics's Interest Coverage falls into.



Five Prime Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Five Prime Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Five Prime Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-92.87 Mil. And its Long-Term Debt & Capital Lease Obligation was $42.31 Mil.

GuruFocus does not calculate Five Prime Therapeutics's interest coverage with the available data.

Five Prime Therapeutics's Interest Coverage for the quarter that ended in Dec. 2020 is calculated as

Here, for the three months ended in Dec. 2020, Five Prime Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-21.98 Mil. And its Long-Term Debt & Capital Lease Obligation was $42.31 Mil.

GuruFocus does not calculate Five Prime Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Five Prime Therapeutics  (NAS:FPRX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Five Prime Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Five Prime Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Five Prime Therapeutics (Five Prime Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. It is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in the pipeline: Cabiralizumab, FPA150, FPT155, and Bemarituzumab.
Executives
William R Ringo director
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
David White officer: See Remarks 4560 HORTON STREET EMERYVILLE CA 94608
Helen Louise Collins officer: EVP and Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451

Five Prime Therapeutics (Five Prime Therapeutics) Headlines

From GuruFocus

Five Prime Announces Closing of Upsized Public Offering of Common Stock

By Business Wire Business Wire 11-18-2020

Five Prime Announces Proposed Public Offering of Common Stock

By Business Wire Business Wire 11-12-2020

Five Prime Therapeutics Reports Second Quarter 2020 Results

By Business Wire Business Wire 08-07-2020